Zhiran Ju
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhiran Ju has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Fen-Er Chen
Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University
6 shared publications - Lijian Ding
Department of Respiratory and Critical Care Medicine, The Affiliated Yangming Hospital of Ningbo University (Yuyao People’s Hospital), Ningbo University
4 shared publications - Yonghong Liu
South China Sea Institute of Oceanology, Chinese Academy of Sciences
4 shared publications - Dang Cheng
Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, China
3 shared publications Junhui Wu
College of Chemical Engineering Zhejiang University of Technology Hangzhou 310014 China
3 shared publicationsSaili Xu
3 shared publications
Latest Publications
- 15 July 2026
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 89 (8) , 2332-2346
Phenolmacrolide A, a Benzenoid Ansamycin from Marine-Derived Streptomyces olivaceus NBUA17 with In Vitro Antipancreatic Cancer Activity, Targets EEF1A2
Ansamycins with diverse ring systems play an indispensable role in the pharmaceutical industry. A novel 20-membered ester-incorporating benzenoid ansamycin, phenolmacrolide A (1), and a new naphthalenoid ansamycin, olimycin I (2), were obtained from the marine-derived Streptomyces olivaceus NBUA17 using a strategy of combining genome mining, SNAP-MS, and HSQC NMR interpretation tools. Furthermore, investigation of the putative ansamycin biosynthetic gene cluster suggested that the novel benzenoid ansamycin scaffold of compound 1 could be formed in part by a hydroxylase and luciferase-like monooxygenase. Compound 1 exhibited moderate activity inhibiting proliferation, migration, and invasion against PANC-1 cells in vitro by inducing cell apoptosis and promoting cancer cell entry into G2/M phase, and inhibiting epithelial-mesenchymal transition. Further drug affinity-responsive target stability assay, molecular docking, cell thermal shift assay, and siRNA transfection identified EEF1A2 as a molecular target of compound 1 in PANC-1 cells. This study identifies an unprecedented subtype within the benzenoid ansamycin family, broadens the structural and bioactive diversity of macrocyclic ansamycins, and underscores the potential of marine-derived actinomycetes as a prolific source of pharmacologically promising lead molecules.
- 15 July 2026
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 89 (8) , 2332-2346
Phenolmacrolide A, a Benzenoid Ansamycin from Marine-Derived Streptomyces olivaceus NBUA17 with In Vitro Antipancreatic Cancer Activity, Targets EEF1A2
Ansamycins with diverse ring systems play an indispensable role in the pharmaceutical industry. A novel 20-membered ester-incorporating benzenoid ansamycin, phenolmacrolide A (1), and a new naphthalenoid ansamycin, olimycin I (2), were obtained from the marine-derived Streptomyces olivaceus NBUA17 using a strategy of combining genome mining, SNAP-MS, and HSQC NMR interpretation tools. Furthermore, investigation of the putative ansamycin biosynthetic gene cluster suggested that the novel benzenoid ansamycin scaffold of compound 1 could be formed in part by a hydroxylase and luciferase-like monooxygenase. Compound 1 exhibited moderate activity inhibiting proliferation, migration, and invasion against PANC-1 cells in vitro by inducing cell apoptosis and promoting cancer cell entry into G2/M phase, and inhibiting epithelial-mesenchymal transition. Further drug affinity-responsive target stability assay, molecular docking, cell thermal shift assay, and siRNA transfection identified EEF1A2 as a molecular target of compound 1 in PANC-1 cells. This study identifies an unprecedented subtype within the benzenoid ansamycin family, broadens the structural and bioactive diversity of macrocyclic ansamycins, and underscores the potential of marine-derived actinomycetes as a prolific source of pharmacologically promising lead molecules.
- Open Access
- 1 April 2026
- Published by KEAI Publishing in Green Synthesis and Catalysis
- Vol. 7 (2) , 138-156
Advances in benzaldehyde lyase-catalyzed biotransformations: From enzyme engineering to industrial applications
- 1 April 2026
- Published by KEAI Publishing in Green Synthesis and Catalysis
- Vol. 7 (2) , 138-156
Open AccessAdvances in benzaldehyde lyase-catalyzed biotransformations: From enzyme engineering to industrial applications
- 27 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (7) , 8645
Correction to “Optimization of Ascidian-Derived Herdmanine D: Targeting Gouty Arthritis via the PPAR-γ/NF-κB/NLRP3 Pathway”
- 27 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (7) , 8645
Correction to “Optimization of Ascidian-Derived Herdmanine D: Targeting Gouty Arthritis via the PPAR-γ/NF-κB/NLRP3 Pathway”
- 27 December 2025
- Published by Elsevier in Molecular Catalysis
- Vol. 591
Chemoenzymatic synthesis of mirabegron using an engineered styrene monooxygenase
- 27 December 2025
- Published by Elsevier in Molecular Catalysis
- Vol. 591
Chemoenzymatic synthesis of mirabegron using an engineered styrene monooxygenase
- 24 December 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Optimization of Ascidian-Derived Herdmanine D: Targeting Gouty Arthritis via the PPAR-γ/NF-κB/NLRP3 Pathway
Gouty arthritis, driven by monosodium urate (MSU) crystal deposition and dysregulated inflammation, remains a therapeutic challenge due to the limitations of current treatments. Here, we investigate Herdmanine D (HDD), a marine-derived alkaloid from the ascidian Herdmania momus. It was optimized via structure-activity relationship (SAR) studies and computational modeling to enhance its binding to peroxisome proliferator-activated receptor γ (PPAR-γ), which regulates the PPAR-γ/NF-κB signaling pathway in gout pathogenesis. The optimized HDD derivative 9a demonstrated potent PPAR-γ binding affinity and pharmacokinetic properties, effectively suppressing NF-κB-driven pro-inflammatory cytokines in vitro. In murine MSU-induced gouty arthritis models, 9a alleviated synovial inflammation and tissue damage. Mechanistically, 9a activated PPAR-γ to inhibit NF-κB and attenuate NLRP3 inflammasome assembly. This work highlights HDD as a unique marine scaffold for next-generation antigout therapeutics, merging marine natural product safety with rational design to address unmet clinical needs.
- 24 December 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Optimization of Ascidian-Derived Herdmanine D: Targeting Gouty Arthritis via the PPAR-γ/NF-κB/NLRP3 Pathway
Gouty arthritis, driven by monosodium urate (MSU) crystal deposition and dysregulated inflammation, remains a therapeutic challenge due to the limitations of current treatments. Here, we investigate Herdmanine D (HDD), a marine-derived alkaloid from the ascidian Herdmania momus. It was optimized via structure-activity relationship (SAR) studies and computational modeling to enhance its binding to peroxisome proliferator-activated receptor γ (PPAR-γ), which regulates the PPAR-γ/NF-κB signaling pathway in gout pathogenesis. The optimized HDD derivative 9a demonstrated potent PPAR-γ binding affinity and pharmacokinetic properties, effectively suppressing NF-κB-driven pro-inflammatory cytokines in vitro. In murine MSU-induced gouty arthritis models, 9a alleviated synovial inflammation and tissue damage. Mechanistically, 9a activated PPAR-γ to inhibit NF-κB and attenuate NLRP3 inflammasome assembly. This work highlights HDD as a unique marine scaffold for next-generation antigout therapeutics, merging marine natural product safety with rational design to address unmet clinical needs.
- 18 September 2025
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 73 (39) , 24845-24854
A New Chemo-Enzymatic Approach to Synthesize Isavuconazole Using an Engineered Benzaldehyde Lyase
Isavuconazole, a clinically important triazole antifungal drug, relies on α-hydroxymethyl ketone as a key synthetic precursor. Here, we present a novel chemo-enzymatic approach for the synthesis of isavuconazole. Using 2,5-difluorobenzaldehyde as the starting material, engineered benzaldehyde lyase (BAL) catalyzes the crucial benzoin reaction to form the key intermediate α-hydroxymethyl ketone. Notably, this biocatalytic process operates without extra cofactors (thiamine pyrophosphate, ThDP) and Mg2+, achieving a time-space yield (TSY) of 17.2 g·L-1·day-1 under optimized conditions. After further chemical reactions on the intermediate, isavuconazole is obtained through an eco-friendly process that outshines traditional chemical synthesis. This optimized protocol is efficient and scalable, yielding isavuconazole at 28.9%, double that of the current industrial chemical process (14.2%), highlighting the remarkable advantages of enzyme-catalyzed synthesis.
- 18 September 2025
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 73 (39) , 24845-24854
A New Chemo-Enzymatic Approach to Synthesize Isavuconazole Using an Engineered Benzaldehyde Lyase
Isavuconazole, a clinically important triazole antifungal drug, relies on α-hydroxymethyl ketone as a key synthetic precursor. Here, we present a novel chemo-enzymatic approach for the synthesis of isavuconazole. Using 2,5-difluorobenzaldehyde as the starting material, engineered benzaldehyde lyase (BAL) catalyzes the crucial benzoin reaction to form the key intermediate α-hydroxymethyl ketone. Notably, this biocatalytic process operates without extra cofactors (thiamine pyrophosphate, ThDP) and Mg2+, achieving a time-space yield (TSY) of 17.2 g·L-1·day-1 under optimized conditions. After further chemical reactions on the intermediate, isavuconazole is obtained through an eco-friendly process that outshines traditional chemical synthesis. This optimized protocol is efficient and scalable, yielding isavuconazole at 28.9%, double that of the current industrial chemical process (14.2%), highlighting the remarkable advantages of enzyme-catalyzed synthesis.
- 28 July 2025
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 88 (8) , 1928-1935
Tailoring of Prematurely Released Polyketide Intermediates in Piericidin Biosynthesis
Piericidins make up a group of microbial-derived polyketide natural products with a wide variety of biological activities. Their biosynthetic gene clusters (BGCs) have been identified in several strains of Streptomyces. In Streptomyces pactum, the piericidin BGC splits into two loci consisting of genes that encode six modular (type I) polyketide synthases and five post polyketide synthase (PKS) modification enzymes. Here, we report that inactivation of the pieA5 gene of the piericidin PKS in a mutant strain of S. pactum, in which several other major biosynthetic pathways have been inactivated, led to the identification of four piericidin polyketide intermediates (1-4) that were offloaded prematurely from the PKS. Compounds 1-3 are derived from an isopropyl starter unit, whereas compound 4 is derived from an acetyl starter unit. Compounds 1 and 4 have a terminal carboxylic acid, whereas compounds 2 and 3 have a terminal amide and a pendant methyl group at C-2. Compound 3 also contains an epoxide ring in the polyketide chain. The results reveal the ability of the piericidin PKS to offload incomplete polyketide intermediates and uncover the highly promiscuous tailoring enzymes that can modify the prematurely released short chain polyketides.
- 28 July 2025
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 88 (8) , 1928-1935
Tailoring of Prematurely Released Polyketide Intermediates in Piericidin Biosynthesis
Piericidins make up a group of microbial-derived polyketide natural products with a wide variety of biological activities. Their biosynthetic gene clusters (BGCs) have been identified in several strains of Streptomyces. In Streptomyces pactum, the piericidin BGC splits into two loci consisting of genes that encode six modular (type I) polyketide synthases and five post polyketide synthase (PKS) modification enzymes. Here, we report that inactivation of the pieA5 gene of the piericidin PKS in a mutant strain of S. pactum, in which several other major biosynthetic pathways have been inactivated, led to the identification of four piericidin polyketide intermediates (1-4) that were offloaded prematurely from the PKS. Compounds 1-3 are derived from an isopropyl starter unit, whereas compound 4 is derived from an acetyl starter unit. Compounds 1 and 4 have a terminal carboxylic acid, whereas compounds 2 and 3 have a terminal amide and a pendant methyl group at C-2. Compound 3 also contains an epoxide ring in the polyketide chain. The results reveal the ability of the piericidin PKS to offload incomplete polyketide intermediates and uncover the highly promiscuous tailoring enzymes that can modify the prematurely released short chain polyketides.
- 9 July 2025
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 15 (14) , 12450-12462
Enantioselective Synthesis of N–N Indole-Pyrrole Atropisomers via Palladium/Chiral Phosphonic Acid Relay Catalysis
- 9 July 2025
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 15 (14) , 12450-12462
Enantioselective Synthesis of N–N Indole-Pyrrole Atropisomers via Palladium/Chiral Phosphonic Acid Relay Catalysis
- Open Access
- 8 April 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 16 (18) , 8108-8113
Enantioselective [5 + 1] cycloaddition of sulfur ylides and vinylethylene carbonates via synergistic palladium/chiral phosphonic acid catalysis
An effective method for the synthesis of dihydropyrans through synergistic palladium and chiral phosphonic acid catalysis was reported. This protocol proceeded under mild reactions and provided dihydropyrans in up to 87% yield and up to 97% ee. Meanwhile, various derivations such as oxidation, Wittig-reaction, reductions, nucleophilic substitution, and Baeyer–Villiger were accomplished to furnish interesting compounds. To gain insight into the reaction mechanism, nonlinear relationship experiments and Hammett plot experiments were carried out. In addition, a range of products (3i, 4b, 4f, 4g, and 4j) accessible from this method exhibit various anti-inflammatory activities on NO and ROS inhibition.
- 8 April 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 16 (18) , 8108-8113
Open AccessEnantioselective [5 + 1] cycloaddition of sulfur ylides and vinylethylene carbonates via synergistic palladium/chiral phosphonic acid catalysis
An effective method for the synthesis of dihydropyrans through synergistic palladium and chiral phosphonic acid catalysis was reported. This protocol proceeded under mild reactions and provided dihydropyrans in up to 87% yield and up to 97% ee. Meanwhile, various derivations such as oxidation, Wittig-reaction, reductions, nucleophilic substitution, and Baeyer–Villiger were accomplished to furnish interesting compounds. To gain insight into the reaction mechanism, nonlinear relationship experiments and Hammett plot experiments were carried out. In addition, a range of products (3i, 4b, 4f, 4g, and 4j) accessible from this method exhibit various anti-inflammatory activities on NO and ROS inhibition.
- 10 March 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (10) , e202500096
Discovery of Safe COX‐2 Inhibitors: Achieving Reduced Colitis Side Effects through Balanced COX Inhibition
The severe adverse effects associated with imbalanced cyclooxygenase‐2 (COX‐2) inhibition continue to pose significant challenges in the development of contemporary anti‐inflammatory drugs. In recent years, the approach to COX‐2 inhibitor drug development has shifted from a focus on highly selective inhibition of COX‐2 to a strategy that emphasizes more moderate selectivity. The amino acid sequence and structural similarities between inducible COX‐2 and constitutive cyclooxygenase‐1 (COX‐1) isoforms present both substantial opportunities and challenges for the design of next generation of balanced COX‐2 inhibitors. As part of our ongoing research into the discovering novel and safer COX‐2 inhibitors, we reported herein a highly potent and balanced COX‐2 inhibitor 21 d (IC50 value=1.35 μM, selectivity profile (IC50 (COX‐1)/IC50 (COX‐2)=22.34)). In vivo assays demonstrated that 21 d significantly alleviated histological damage and provided robust protection against dextran sulfate sodium (DSS)‐induced acute colitis.
- 10 March 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (10) , e202500096
Discovery of Safe COX‐2 Inhibitors: Achieving Reduced Colitis Side Effects through Balanced COX Inhibition
The severe adverse effects associated with imbalanced cyclooxygenase‐2 (COX‐2) inhibition continue to pose significant challenges in the development of contemporary anti‐inflammatory drugs. In recent years, the approach to COX‐2 inhibitor drug development has shifted from a focus on highly selective inhibition of COX‐2 to a strategy that emphasizes more moderate selectivity. The amino acid sequence and structural similarities between inducible COX‐2 and constitutive cyclooxygenase‐1 (COX‐1) isoforms present both substantial opportunities and challenges for the design of next generation of balanced COX‐2 inhibitors. As part of our ongoing research into the discovering novel and safer COX‐2 inhibitors, we reported herein a highly potent and balanced COX‐2 inhibitor 21 d (IC50 value=1.35 μM, selectivity profile (IC50 (COX‐1)/IC50 (COX‐2)=22.34)). In vivo assays demonstrated that 21 d significantly alleviated histological damage and provided robust protection against dextran sulfate sodium (DSS)‐induced acute colitis.